

## abemaciclib (VERZENIO)

### Diagnoses Considered for Coverage:

- Hormone receptor (HR)-positive HER2-negative breast cancer treatment – advanced disease
- Early breast cancer, hormone receptor-positive, HER2-negative, node-positive, high-risk, in combination with adjuvant endocrine therapy

### Coverage Criteria:

For treatment of advanced, recurrent, refractory, or metastatic disease breast cancer:

- Dose does not exceed 400 mg per day, **and**
- Cancer is hormone receptor positive (HR+) and HER2-negative (HER2-), **and**
- Patient is male or a postmenopausal female or premenopausal female receiving ovarian ablation or suppression, **and**
- One of the following:
  - Being used in combination with either an aromatase inhibitor or fulvestrant, **or**
  - Being used as monotherapy, and patient has received has prior endocrine therapy and chemotherapy

For early breast cancer and adjuvant therapy:

- Cancer is hormone receptor positive (HR+) and HER2-negative (HER2-), **and**
- Being used with endocrine therapy (tamoxifen or an aromatase inhibitor), **and**
- Patient is at high-risk of disease recurrence (i.e., 4 or more positive lymph nodes, 1-3 positive lymph nodes with one of more of the following: Grade 3 disease, or Tumor size  $\geq 5$  cm), **and**
- Dose does not exceed 150 mg twice daily.

**Coverage Duration:** one year

Effective Date: 09/27/2023